- Home
- AIRS vs CLLS Comparison
AIRS vs CLLS Comparison
Compare AIRS & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRS | CLLS |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 384.3M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AIRS | CLLS |
|---|---|---|
| Price | $2.74 | $3.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 4.7M | 45.7K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $151,818,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.51 | $1.10 |
| 52 Week High | $12.00 | $5.48 |
Technical Indicators
Market Signals| Indicator | AIRS | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 48.18 |
| Support Level | $1.73 | $3.32 |
| Resistance Level | $3.27 | $3.83 |
| Average True Range (ATR) | 0.46 | 0.20 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 57.40 | 59.18 |
Price Performance
Historical ComparisonAbout AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.